| Symbol | FTRE |
|---|---|
| Name | FORTREA HOLDINGS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 8 MOORE DRIVE, DURHAM, North Carolina, 22709, United States |
| Telephone | 877-495-0816 |
| Fax | — |
| — | |
| Website | https://www.fortrea.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001965040 |
| Description | Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. It offers phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. is based in Durham, North Carolina. Additional info from NASDAQ: |
2026-06-12 20:18
Director SANDERS MACHELLE 🟡 adjusted position in 12.9K shares (2 derivative) of Fortrea Holdings Inc. (FTRE) Transaction Date: Jun 10, 2026 | Filing ID: 000086
Read more
2026-06-12 20:17
Director Smith David Ross 🟡 adjusted position in 5.4K shares (2 derivative) of Fortrea Holdings Inc. (FTRE) at $16.34 Transaction Date: Jun 10, 2026 | Filing ID: 000085
Read more
2026-06-12 20:15
Director Pesicka Edward A 🟡 adjusted position in 12.9K shares (2 derivative) of Fortrea Holdings Inc. (FTRE) Transaction Date: Jun 10, 2026 | Filing ID: 000084
Read more
2026-06-12 20:13
Director NEUPERT PETER M 🟢 acquired 12.9K shares (1 derivative) of Fortrea Holdings Inc. (FTRE) Transaction Date: Jun 10, 2026 | Filing ID: 000083
Read more
2026-06-12 20:10
Morais Mark A. 🔴 sold 4.7K shares of Fortrea Holdings Inc. (FTRE) at $16.82 Transaction Date: Jun 10, 2026 | Filing ID: 000082
Read more
2026-06-12 20:09
Director Ray Amrit 🟡 adjusted position in 12.9K shares (2 derivative) of Fortrea Holdings Inc. (FTRE) Transaction Date: Jun 10, 2026 | Filing ID: 000081
Read more
2026-06-12 20:08
Director Sharbaugh William J 🟢 acquired 12.9K shares (1 derivative) of Fortrea Holdings Inc. (FTRE) Transaction Date: Jun 10, 2026 | Filing ID: 000080
Read more
2026-06-12 20:07
Director Russell Erin L 🟡 adjusted position in 12.9K shares (2 derivative) of Fortrea Holdings Inc. (FTRE) Transaction Date: Jun 10, 2026 | Filing ID: 000079
Read more
2026-06-10 20:15
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07244705 | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally… | Phase1 | Colorectal Cancer (Diagnosis) | Recruiting | 2025-11-01 | 2028-07-01 | ClinicalTrials.gov |
| NCT07017933 | Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surger… | Na | Renal Impairment After Cardiac Surgery | Recruiting | 2025-07-16 | 2027-06-14 | ClinicalTrials.gov |
| NCT07093398 | A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Hea… | Phase1 | Healthy Adult Volunteers | Completed | 2025-07-11 | 2025-11-17 | ClinicalTrials.gov |
| NCT06933472 | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphos… | Phase3 | Hyperphosphatemia | Recruiting | 2025-06-13 | 2027-01-10 | ClinicalTrials.gov |
| NCT06713369 | AZD5305 hADME in Patients With Advanced Solid Malignancies | Phase1 | Locally Advanced or Metastatic Solid Tumor | Recruiting | 2025-04-02 | 2026-10-02 | ClinicalTrials.gov |
| NCT06769633 | Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 … | Phase2 | Duchenne Muscular Dystrophy | Recruiting | 2025-01-02 | 2029-12-01 | ClinicalTrials.gov |
| NCT06813781 | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, … | Phase1 | Hepatic Impairment | Completed | 2024-12-19 | 2025-10-02 | ClinicalTrials.gov |
| NCT06692764 | A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure | Phase2 | Atherosclerotic Cardiovascular Disease | Completed | 2024-10-30 | 2025-05-02 | ClinicalTrials.gov |
| NCT06563102 | Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Thera… | Phase4 | Mild Asthma | Completed | 2024-09-11 | 2026-02-24 | ClinicalTrials.gov |
| NCT06398730 | A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Sa… | Phase1 | Healthy Volunteers | Completed | 2024-07-02 | 2026-02-23 | ClinicalTrials.gov |
| NCT06432647 | A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-11… | Phase1 | Healthy Volunteers | Completed | 2024-04-24 | 2024-11-25 | ClinicalTrials.gov |
| NCT05933057 | Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With D… | Phase3 | Duchenne Muscular Dystrophy | Recruiting | 2024-02-19 | 2028-02-01 | ClinicalTrials.gov |
| NCT06083012 | Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an A… | — | Atrial Fibrillation | Active_Not_Recruiting | 2023-10-27 | 2027-04-27 | ClinicalTrials.gov |
| NCT05693129 | Pediatric Patients Aged 1 to 6 Years With APDS | Phase3 | APDS | Active_Not_Recruiting | 2023-08-30 | 2028-10-28 | ClinicalTrials.gov |
| NCT05981495 | Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection K… | — | Tuberculosis, Pulmonary | Unknown | 2023-08-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT05636852 | Altropane Dose for Imaging Patients With Suspected Parkinson's Disease | Phase2 | Parkinson Disease | Terminated | 2023-04-24 | 2024-06-08 | ClinicalTrials.gov |
| NCT05438407 | Pediatric Patients Aged 4 to 11 Years With APDS | Phase3 | APDS | Active_Not_Recruiting | 2023-02-01 | 2026-12-30 | ClinicalTrials.gov |
| NCT04817670 | Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With S… | Phase2 | Sickle Cell Disease | Completed | 2021-11-18 | 2024-03-07 | ClinicalTrials.gov |
| NCT04702451 | Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation | Na | Atrial Fibrillation | Completed | 2021-02-12 | 2023-12-27 | ClinicalTrials.gov |
| NCT04498026 | Adherus™ Dural Sealant in Spinal Procedures | Na | Spinal Duraplasty | Enrolling_By_Invitation | 2020-11-19 | 2025-12-01 | ClinicalTrials.gov |
Total clinical trials: 20
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05693129 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| PVI | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04702451 |
| VX1 | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04702451 |
| Dispersion ablation + PVI | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04702451 |
| NanoDetect-TB | Other | Preclinical | Tuberculosis, Pulmonary | UNKNOWN | NCT05981495 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
| ATH-1105 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
| Placebo TID | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| Placebo BID | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| VIT-2763 240 mg | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| VIT-2763 360 mg | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| VIT-2763 120 mg | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| DuraSeal Exact Dural Sealant System | Other | Approved | Spinal Duraplasty | ENROLLING_BY_INVITATION | NCT04498026 |
| Adherus Dural Sealant System | Other | Approved | Spinal Duraplasty | ENROLLING_BY_INVITATION | NCT04498026 |
| Placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | RECRUITING | NCT05933057 |
| Givinostat | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | RECRUITING | NCT05933057 |
| Givinostat Hydrochloride - Cohort 2 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | RECRUITING | NCT06769633 |
| Givinostat Hydrochloride | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | RECRUITING | NCT06769633 |
| Altropane (123I) Injection | Other | Phase PHASE2 | Parkinson Disease | TERMINATED | NCT05636852 |
| AZD5004 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06813781 |
| AZD5004 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06813781 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07219238 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05693129 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Bevacizumab (Avastin) | Other | Phase PHASE1 | Colorectal Cancer (Diagnosis) | RECRUITING | NCT07244705 |
| Tislelizumab | Other | Phase PHASE1 | Colorectal Cancer (Diagnosis) | RECRUITING | NCT07244705 |
| ABT-301 | Other | Phase PHASE1 | Colorectal Cancer (Diagnosis) | RECRUITING | NCT07244705 |
| Cardiac mapping | Other | Preclinical | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06083012 |
| AP301 Low Dose | Other | Phase PHASE3 | Hyperphosphatemia | RECRUITING | NCT06933472 |
| AP301 | Other | Phase PHASE3 | Hyperphosphatemia | RECRUITING | NCT06933472 |
| AZD0780 | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT06692764 |
| Placebo | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT06692764 |
| Albuterol | Other | Phase PHASE4 | Mild Asthma | COMPLETED | NCT06563102 |
| Albuterol/Budesonide | Other | Phase PHASE4 | Mild Asthma | COMPLETED | NCT06563102 |
| [14C]-AZD5305 (therapeutic dose) | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumor | RECRUITING | NCT06713369 |
| [14C]-AZD5305 microtracer | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumor | RECRUITING | NCT06713369 |
| Saruparib (AZD5305) | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumor | RECRUITING | NCT06713369 |
| Static - PET/CT scan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06398730 |
| GEH200520 Injection and GEH200521 (18F) Injection | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06398730 |
| Salbutamol | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Mannitol | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Albuterol/budesonide (AIRSUPRA®) | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Budesonide/formoterol | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Tezepelumab | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Renal assist device | Device | Approved | Renal Impairment After Cardiac Surgery | RECRUITING | NCT07017933 |
| D3S-001 | Other | Phase PHASE1 | Healthy Adult Volunteers | COMPLETED | NCT07093398 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| Investigator's choice of treatment | Drug | Phase PHASE4 | Chronic Lymphocytic Leukaemia | RECRUITING | NCT06651970 |
| Acalabrutinib | Other | Phase PHASE4 | Chronic Lymphocytic Leukaemia | RECRUITING | NCT06651970 |
| Tezepelumab | Other | Phase PHASE3 | Chronic Rhinosinusitis With Nasal Polyps | RECRUITING | NCT06706817 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5004 | DRUG | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06813781 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
| ATH-1105 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
Total products: 89